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Abstract
Background: Wound infection affects a considerable portion of patients after abdominal operations, increasing
health care costs and postoperative morbidity and affecting quality of life. Antibacterial coating has been
suggested as an effective measure to decrease postoperative wound infections after laparotomies. The INLINE
metaanalysis has recently shown the superiority of a slowly absorbable continuous suture for abdominal closure;
with PDS plus
® such a suture has now been made available with triclosan antibacterial coating.
Methods/Design: The PROUD trial is designed as a randomised, controlled, observer, surgeon and patient blinded
multicenter superiority trial with two parallel groups and a primary endpoint of wound infection during 30 days
after surgery. The intervention group will receive triclosan coated polydioxanone sutures, whereas the control
group will receive the standard polydioxanone sutures; abdominal closure will otherwise be standardized in both
groups. Statistical analysis is based on intention-to-treat population via binary logistic regression analysis, the total
sample size of n = 750 is sufficient to ensure alpha = 5% and power = 80%, an interim analysis will be carried out
after data of 375 patients are available.
Discussion: The PROUD trial will yield robust data to determine the effectiveness of antibacterial coating in one of
the standard sutures for abdominal closure and potentially lead to amendment of current guidelines. The
exploration of clinically objective parameters as well as quality of life holds immediate relevance for clinical
management and the pragmatic trial design ensures high external validity.
Trial Registration: The trial protocol has been registered with the German Clinical Trials Register (DRKS00000390).
Background
Rationale
Postoperative surgical site infections (SSI) are one of the
most common complications after laparotomy. Many
strategies have been developed to reduce this burden
such as the introduction of less invasive procedures (e.g.
laparoscopic interventions) but still most of the intraab-
dominal procedures are performed as open surgeries
worldwide. Preoperative antibiotic prophylaxis besides
routine use of effective and persistent skin antisepsis as
well as avoidance and/or control of contamination were
amongst the most effective interventions introduced in
the last century to reduce SSI.
Currently about 12% of patients undergoing elective
open colorectal procedures develop an SSI [1]. This is in
accordance with the “Hospital in Europe Link for Infec-
tion Control through Surveillance” (HELICS) SSI statis-
tical report that has reported a similar incidence of SSI
[2]. The INSECT multicenter RCT focussing on differ-
ent strategies for abdominal fascia closure after elective
primary midline laparotomy in various surgical indica-
tions detected a wound infection rate of 16% as a sec-
ondary outcome [3]. Therefore further efforts are
necessary to reduce this problem which may cause
impairment of the patients’ quality of life, require addi-
tional wound therapy treatment, lead to prolongation of
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any medium, provided the original work is properly cited.hospital stay or delay of further relevant treatments (e.g.
start of adjuvant chemotherapy) and increases the risk
for further complications such as wound dehiscence or
burst abdomen requiring additional surgery [4]. Today
75% of all SSI are superficial incisional infections
whereas the remaining 25% are deep incisional or deep
organ space SSI.
Patient-related factors such as comorbidities (e.g. dia-
betes mellitus) or life style habits (e.g. smoking) have to
be taken into account but are difficult to change once
an intervention is needed. Therefore further efforts on
the surgeon’s side are required to reduce the frequency
of SSI. Any foreign material such as sutures needed for
closure of the abdominal fascia increases the risk of a
SSI, and it has been shown that bacteria not only colo-
nize wound tissues but the actual suture itself. Therefore
various suture materials have been investigated for sev-
eral decades to improve wound healing and reduce
infection rates [5].
Preliminary data
Triclosan is an antiseptic known to interfere with
microbial lipidsynthesis [6] and has been used to cover
suture material in order to reduce SSI. Two recent his-
torically controlled studies comparing the interrupted
closure of the abdominal fascia with a triclosan-coated
braided rapidly absorbable suture material (polyglactin
910, Vicryl plus
®) versus a slowly absorbable continu-
ous loop suture (polydioxanone, PDS II
®)i np a t i e n t s
with elective or emergency surgery demonstrated a
highly significant reduction of wound infections using
the coated material [7,8]. This is in accordance with
data from in vitro studies showing a considerable
decrease in bacterial adherence with triclosan-coated
sutures [9]. Two more studies demonstrated antibac-
terial efficacy of the triclosan-coating in Vicryl sutures
in experimental large animal studies [10,11]. So far,
however, only one multicenter randomized controlled
trial comparing the non-coated with the coated PDS
suture has been conducted but not yet published (Bar-
a c sJ ,H u s z á rO ,H o r v á t hÖ :A b d o m i n a lW a l lC l o s u r e
With Triclosan-coated Suture; NCT01123616.). After
elective midline incisions the abdominal fascia should
be closed with a slowly absorbable continuous suture
for best prevention of incisional hernias according to
the results of a recent systematic review and meta-ana-
lysis [12]. Whether coating of the sutures with antibac-
terial substances is beneficial in clinical practice has
yet to be determined.
SSI is not a problem of open colorectal surgery alone.
The study populations of the INSECT Trial and the his-
torically controlled studies by Justinger et al are cover-
ing a much larger spectrum of patients and therefore a
reduction of SSI should be demonstrable in all these
patients [3,7,8] Thus, the PROUD trial was planned as a
multicenter effectiveness RCT to investigate if SSI can
be clinically relevant reduced with a triclosan-coated
PDS suture.
Objective and hypotheses
The objective of the PROUD trial is to yield reliable
data on the effectiveness of triclosan-coated PDS suture
for abdominal facia closure in preventing SSI compared
to non-coated PDS sutures. The null hypothesis to be
tested in confirmatory analysis states that the rate of
superficial and deep incisional SSI within 30 days after
midline incision is equal in both treatment groups.
Methods/Design
Trial locations
The trial locations comprise 22 surgical departments of
secondary and tertiary care across Germany (Table 1).
Trial population and eligibility criteria
Patients who will undergo elective and midline abdom-
inal laparotomy for any reason will be recruited for this
trial. All patients will be informed about the purpose of
the trial, the operation modalities, and their benefits as
well as risks. Patients will be asked whether they are
prepared to participate in the trial prior to their inclu-
sion. After being screened for the inclusion and exclu-
sion criteria eligible patients will be included into the
trial. Patients who were screened but not enrolled in the
trial (including patients unable to give informed consent
due to any reason) will be documented in the screening
log, recording the reason for exclusion.
Inclusion criteria
￿ Age equal or greater than 18 years




￿ Participation in another intervention-trial with
interference of intervention and/or outcome of this
study
￿ Impaired mental state or language problems
Sample size
375 patients per group (including the expected drop
outs) will be randomized for this trial, accounting for a
total of 750 patients. This number of patients may be
changed based on the results of an adaptive interim ana-
lysis, which will be performed after availability of results
for the primary endpoint for a total of 375 randomized
patients (i.e. 50% of required patients for a fixed sample
size design). The maximum sample size is 1200 patients.
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Multicenter observer, surgeon and patient blinded adap-
tive randomized surgical trial with two parallel groups.
For trial flow chart please cf. Figure 1.
Recruitment and trial timeline
Patient recruitment started in April 2010 as a single
center trial. The start date of multicenter recruitment
was in January 2011. The interim analysis is expected to
be performed at the latest in September 2011, after data
of 375 randomized patients are available. Depending on
results of the interim analysis further proceedings and
timeline will be defined.
Baseline data
If a patient has given informed consent the baseline
demographic and clinical data are documented including
assessement of quality of life with the EQ-5D™ instru-
ment. Date of surgery, antibiotic prophylaxis/therapy
and surgical intervention have to be reported as well as
wound status (clean, clean-contaminated, contaminated)
and blood loss. The surgeon performing the abdominal
wall closure and his surgical expertise are recorded.
Randomization
Patients will be randomized to one of the two treatment
groups just before closure of the abdominal wall by
using a web-based tool (Randomizer
© Software [13]).
In order to achieve comparable groups for known and
unknown risk factors randomization will be performed
as block randomization with a 1:1 allocation.
A sufficient number of patients will be recruited
according to the sample size calculation in order to
minimize random error.
Blinding
Participating surgeons should not be influenced in their
abdominal wall closure performance and have to follow
the protocol in all patients. The two suture materials
cannot be differentiated by color, feel or smell; further-
more, identical needles (CTX 48 mm 1/2c) are used and
therefore the surgeon cannot identify whether the suture
i sc o a t e do rn o t .T h es u t u r ew i l lb eh a n d e dt ot h es u r -
geon in a blinded fashion by the scrub nurse to prevent
unblinding by viewing the wrapper.
Patients are blinded for the type of suture they
received to ensure valid assessement of quality of life;
Table 1 Trial Locations (Germany)
Institutions Principal Investigators
Department of General and Visceral Surgery, Campus Mitte, Charite-Universitaetsmedizin Berlin, Berlin Prof. Dr. Joachim M. Müller
PD Dr. Jens Neudecker
Department of General, Visceral and Transplantation Surgery, Virchow Klinikum, Charite-Universitaetsmedizin
Berlin, Berlin
PD Dr. Daniel Seehofer
Gemeinschaftskrankenhaus Havelhöhe, Medizinische Klinik Schwerpunkt Chirurgie, Berlin PD Dr. Hans-Peter Lemmens
Department of Surgery, Vivantes Klinikum Neukölln, Berlin Prof. Dr. Bartholomäus Böhm
Department of General, Visceral and Minimally Invasive Surgery, Park-Klinik Weissensee, Berlin PD Dr. Georg Arlt
Department of General and Visceral Surgery, Sana Klinikum Lichtenberg, Berlin Prof. Dr. Klaus Gellert
Department of General and Visceral Surgery, St. Josef Krankenhaus Berlin Tempelhof, Berlin Prof. Dr. Reiner Kunz
Department of General and Visceral Surgery, Unfallkrankenhaus Berlin, Berlin Dr. Henryk Thielemann
Department of General, Visceral and Trauma Surgery, St.-Josefs-Hospital Dortmund-Hörde, Dortmund Dr. Erwin Stein
Division of General and Visceral Surgery, University Medical Center Freiburg, Freiburg Prof. Dr. Oliver Thomusch
Department for General and Visceral Surgery, Universitaetsmedizin Goettingen, Goettingen Prof. Dr. Heinz Becker
Department for General and Visceral Surgery, Asklepios Klinik Harburg, Hamburg Prof. Dr. Friedrich Kallinowski
Department of Surgery, Krankenhaus Salem, Heidelberg PD Dr. Moritz v. Frankenberg
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg Dr. Markus Diener
Department of General, Visceral and Trauma Surgery, Krankenhaus der Augustinerinnen, Koeln Prof. Dr. K. Tobias E. Beckurts
Department of Surgery, University Medical Center Schleswig-Holstein, Campus Luebeck, Luebeck PD Dr. Dr. Uwe J. Roblick
Department of General and Abdominal Surgery, Johannes Gutenberg-University Hospital, Mainz. Dr. Boris Jansen-Winkeln
Department of Surgery, University Hospital Campus Grosshadern, Muenchen Prof. Dr. Karl-Walter Jauch
Department of Surgery, Klinikum Neumarkt, Neumarkt Dr. Manfred Kästel
Department of Surgery, Visceral, Thoracic and Vascular Surgery, Ernst Moritz Arndt University, Greifswald, Germany Prof. Dr. med. Claus-Dieter
Heidecke
Department of General, Visceral and Thoracic Surgery, Klinikum am Steinenberg Reutlingen, Reutlingen Prof. Dr. Thomas Zimmermann
Dr. René Hodina
Department of General, Visceral and Thoracic Surgery, Marienhospital, Stuttgart Dr. Julius Pochhammer
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as well. Furthermore, photographs of the abdominal
wound are assessed by an independent Primary Out-
come Validation Committee (POVC) consisting of three
board certified surgeons who independently review all
photographs without knowledge of the origin.
Interventions
Patients undergo routine scrub and site preparation
according to the established standards of the participat-
ing centers. An antibiotic prophylaxis/therapy must be
performed and documented according to recently
updated national guidelines of the Paul-Ehrlich
Gesellschaft für Chemotherapie e.V. [14]. Antibiotics
must be given prior to incision of the skin.
The operation is initiated with skin incision per-
formed with electric cautery (yellow = cutting function:
working with alternating cur r e n t ,t h et i s s u ei sh e a t e d
abruptly more than 100°C, in a way that the vapor
pressure ruptures the cellular membranes explosively).
The subcutaneous layer is cut with electric cautery
(blue = coagulation function: heating of the tissue with
alternating current-effectual slowly-approximately at
100°C to vapor the intra- and extra-cellular matrix.
Tissue and vessels are shrinking, hemostasis occurs).
The abdominal fascia is cut in the midline with electric
Figure 1 Flow Chart PROUD Trial (see separate.jpg file). Timeline and course of trial participants.
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and then the incision of the peritoneum is completed
with electric cautery (blue). The surgical procedure is
carried out as usual and according to local standards
regarding the indication for the intervention. Docu-
mentation of wound status, surgical procedure and in
case of stoma formation is mandatory in all rando-
mized patients.
Patients are randomized to one of the two treatment
groups just before closure of the abdominal wall.
Four Mikulicz clamps or equivalent clamps are placed
at the edges of the abdominal fascia. In both treatment
groups closure of the abdominal wall is started either
from the cranial end (surgeon is on the right side of the
patient) or from the caudal end (surgeon is on the left
side of the patient) of the wound. The peritoneum is
not closed by a separate suture.
Trial intervention
Closure of abdominal fascia with triclosan-coated con-
tinuous polydioxanone suture (PDS * PLUS PDP9262;
lot: CA6417, CLZ854 and CLM544; needle: CTX 48
mm 1/2c.).
Control intervention
Closure of abdominal fascia with polydioxanone suture
(PDS*II Z1950; lot: CB8CGLQ0, CK8DRLQ0,
CL8GBHQ0, CJ8KJLQ2 and CL8GBHQ0; needle: CTX
48 mm 1/2c).
Labels of used sutures are sent to the Institute for Medi-
cal Biometry and Informatics, University of Heidelberg, to
document use of suture for a given randomized patient.
The abdomen will be closed by a continuous mass clo-
sure technique using two loops of the suture. Each loop
has to be stretched once by the scrub nurse before use, in
order to avoid breakage of the material. The first stitch
has to be anchored cranially and caudally of the incision.
The peritoneum should not be stitched to prevent
entrapment between the fascial edges. After having
closed half of the wound, one end of the loop is cut right
below the needle. After one stitch back to the opposite
edge of the fascia both ends are tied with at least four
counterrotating knots. The same is done with the loop
from the caudal end of the wound with intersecting the
other loop at the middle of the incision with an overlap
of both suture lines of at least 2 cm. Both loops may not
be tied together. For every patient two loops must be
used, irrespective of the length of the wound.
The distance between the stitches should maximally
be 1,5 cm and the distance from the edge of the fascia
should be at least 1,5 cm. The subcutaneous tissue is
not sutured and no subcutaneous drainage is used. The
skin is closed with clips.
The expertise of the surgeon (board certified versus
no certificate) as well as the number of prior abdominal
wall closures at the closure will be documented.
Permitted and not permitted medication(s)/treatment(s)
No suture material or suture technique other than
described in the protocol can be used for fascia closure.
Patients have to receive antibiotic prophylaxsis prior to
the incision and the fascia has to be closed using the
appropriate suture to which they are randomized. Any
protocol violation has to be reported with a clear
description in the CRF.
Postoperative care is performed according to the prin-
ciples and standard of the department (artificial organ
support, antibiotics, pain treatment, fluid resuscitation,
nutrition). Length of intensive care unit stay and dis-
charge date are documented.
Risks
No additional risks are expected for participants, since
both sutures are readily commercially available after ful-
filling requirements for approval by several international
authorities. There have been reports on several suspected
cases of allergic contact dermatitis towards triclosan-
coated sutures, none of which could be verified [15].
Outcomes (primary and secondary) and assessment
The primary endpoint superficial and deep incisional
surgical site infection according to Center for Disease
Control (adapted from [16]) within 30 days after surgery
will be assessed during two following study visits by the
outcome assessors in the participating centers (Table 1).
In addition a photograph is taken at each follow up visit
and sent to the Study Center of the German Surgical
Society for evaluation by the Primary Outcome Valida-
tion Committee (POVC). The committee members will
categorize independently which of the following applies
for the primary endpoint: (1) SSI present; (2) SSI not
present; (3) Wound not assessable. Depending on this
information patients will be classified as to whether they
have met the primary endpoint or not.
Secondary endpoints include duration of surgery,
length of incision (fascia), frequency of wound dehiscence
(with or without evisceration), frequency of re-operation
due to wound dehiscence, postoperative intensive care
unit stay, postoperative hospital stay, 30 day mortality
and quality of life (QoL); the latter will be assessed by the
EQ-5D™ questionnaire filled in by the patient.
Study visits
From screening to day 30 postoperatively there will be 4
study visits, assessing demographics and baseline clinical
data, eligibility criteria, randomisation, surgical
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life and safety; please cf. table 2 for detailed information.
Data management
All protocol-required information collected during the
trial is entered by the investigator, or designated repre-
sentative, in a paper-based CRF. Patients fill out the
quality of life questionnaires themselves. Photographs
are uploaded in a centralized database by investigators.
Two weeks after a patient has completed the trial all
information must be sent to the Institute of Medical
Biometry and Informatics Heidelberg (IMBI) for data
entry. Copies remain at the participating site for further
clarifications. An explanation should be given for all
missing data.
In order to ensure that the database reproduces the
CRFs correctly, the IMBI accomplishes a double entry
of data. The completeness, validity and plausibility of
data are examined by validating programs, which
thereby generate queries. The sites are obliged to clarify
or explain the queries. At the end of the trial the princi-
ple investigator will retain the originals of all CRFs.
The data will be managed and analyzed according to
the appropriate SOPs valid in the IMBI.
Monitoring
Participating investigators must agree to allow trial-
related monitoring, including audits, ethics committee
review and regulatory inspections by providing direct
access to source data/documents as required. Patients’
informed consent for this will also be obtained.
Monitoring will be performed using different strate-
gies and in accordance with ICH-GCP Section 5.18.
First recruitment of patients within centers will be
centrally monitored by the webbased randomization
tool through the Study Centre of the German Surgical
Society (SDGC). If centers do not recruit a patient
within a time frame of two weeks they will be con-
tacted. If a center is not able to recruit a patient within
four weeks actions will be taken including closure of
sites.
Performance of follow up visits including photos will
be monitored two weeks after the final visit by the
IMBI. If centres do not perform according to protocol
they will be notified and if more than 40% of patients
randomized are not evaluable for the primary endpoint
(missing photo documentation) they may be closed. On-
site monitoring visits may be scheduled where there is
evidence or suspicion of non-compliance by a site with
important aspects of the trial requirements. Sites will be
sent a letter in advance outlining the reasons for the
visit, a list of documents that are to be reviewed, inter-
views that will be conducted, planned inspections of
facilities and who will be performing the visit.
Following the monitoring visit, the monitor will pro-
vide to the site a report which will summarize the docu-
ments reviewed, along with a statement of findings,
deviations, deficiencies, conclusions and actions taken or
recommended.
Safety evaluation, analysis and reporting
A serious adverse event (SAE) is any adverse event
occurring at any time during the period of observation,
that results in death, is immediately life-threatening,
requires or prolongs hospitalization and/or results in
persistent or significant disability or incapacity.
From the moment the subject has signed informed
consent until the regular end of the trial at 30 days fol-
low up or until premature withdrawal of the patient, all
SAE must be documented on a “serious adverse event
form” available from the investigator study file.
The following conditions are expected after the initial
operation and will therefore not be classified as compli-
cation: pain, nausea, vomiting, urinary tract infection,
hyper-/hypotension, imbalances of blood sugar or elec-
trolytes and other lab values out of range, if they are
not exceeding the duration and extent that can be
expected after surgery.
SAE need to be reported to the SDGC once they are
noticed by the investigator within a time frame of five
days. The safety analysis will be based on the set of all
patients for which one of the interventions was applied.






(Discharge or latest on day 10)
4
(30 days post OP)
Demographics and baseline clinical data X
Eligibility criteria X
Randomisation, surgical intervention X
Clinical visit XX
Photo documentation of wound X X
Quality of life X X X
Safety X X X
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will be presented; severity and relationship to the inter-
vention will be given and compared between the groups.
The Data Safety Monitoring Board will be provided an
annual report of SAE during the conduction of the trial.
Statistical methods
Superficial and deep incisional surgical site infection
rates for patients in the PDS II
® group are estimated to
occur at a rate of 0.12 [1,2]. The trials by Justinger have
shown a reduction of SSI of more than 50% (from
10.8% to 4.9% and from 9.2% to 4.3% respectively).
Therefore, we estimate a rate of 0.06 for PDS Plus
®.
For a fixed sample size design, the sample size
required to achieve a power of 1-b =0 . 8 0f o rt h eo n e -
sided chi-square test at level a = 0.025 under these
assumptions amounts to 2 × 356 = 712 (nQuery Advi-
sor
®, version 7.0). It can be expected that including cov-
ariates of prognostic importance in the logistic
regression model as defined for the confirmatory analy-
s i sw i l li n c r e a s et h ep o w e ra sc o m p a r e dt ot h ec h i -
square test. As the individual results for the primary
endpoint are available within 30 days after surgery, the
drop-out rate is expected to be small. Nevertheless, a
potential dilution of the treatment effect due to drop-
outs is taken into account (e.g. no photographs available,
loss to follow up); it is assumed that this can be com-
pensated by additional 5% of patients to be randomized,
and therefore the total sample size required for a fixed
sample size design amounts to n = 712 + 38 = 750
patients.
To account for the remaining uncertainty about the
assumed treatment effect and the overall SSI rate, an
adaptive interim analysis is performed after the results
for the primary endpoint are available for a total of 375
evaluable patients. If the study is continued with a sec-
ond stage, the sample size can be recalculated using the
information obtained from the results of the interim
analysis. The actually achieved sample size is then not
fixed but random, and a variety of scenarios can be con-
sidered. If the sample size is calculated under the same
assumptions with respect to the SSI rates for the two
groups, applying the same the overall significance level
of a = 0.025 (one-sided) but employing additionally the
defined stopping boundaries and recalculating the sam-
ple size for the second stage at a conditional power of
80% on the basis of the SSI rates observed in the
interim analysis results in an average total sample size
of n = 766 patients; the overall power of the study is
then 90% (ADDPLAN
®, version 5.0).
Confirmatory analysis of the primary endpoint
The null-hypothesis of equal rates of superficial and
deep incisional SSI within 30 days after midline incision
is tested with a logistic regression model including the
covariates age, center, surgeon’s experience, and BMI.
An overall one-sided significance level of a =0 . 0 2 5i s
applied. Confirmatory analysis of the primary endpoint
will be primarily based on the full analysis set which is
consistent with the intention-to-treat (ITT) principle by
including all patients who were randomized to one of
the intervention groups. This approach reflects the idea
that the study results should match as close as possible
to the conditions in clinical practice. However, an eva-
luation of the per-protocol set where patients with
major protocol violations are excluded is performed
additionally and the results are compared with those of
the ITT analysis. If a patient discontinues from the
study prematurely without having suffered an SSI, miss-
ing data for the primary outcome variable will be
replaced by using the ICA-r method described by Hig-
gins et al. 2008 [17]. Additionally, sensitivity analyses
will be performed by applying alternative methods deal-
ing with missing data such as, e.g., complete case
analysis.
Analysis of secondary variables
The secondary variables will be analyzed descriptively by
tabulation of the measures of the empirical distributions.
Descriptive p-values of the corresponding statistical tests
comparing the intervention groups and associated 95%
confidence intervals will be given. For the purpose of
hypothesis generation for future trials, subgroup ana-
lyses will be performed for patients with different
wound status, different severity of wound infection and
for patients with and without an applied stoma.
Adaptive interim analysis
An adaptive interim analysis [18] will be performed after
availability of the results for the primary endpoint for a
total of 375 randomized patients (i.e., 50% of the num-
ber of patients required in a fixed sample size design).
The following type I error rates and decision boundaries
for the interim and the final analysis are specified:
￿ overall one-sided type I error rate: 0.025
￿ boundary for the one-sided p-value of the first
stage for accepting the null-hypothesis within the
interim analysis: a0 = 0.5
￿ one-sided local type I error rate for testing the
null-hypothesis within the interim analysis: a1 =
0.0102
￿ boundary for the product of the one-sided p-values
of both stages for the rejection of the null-hypothesis
in the final analysis: ca = 0.0038
If the trial will be continued with a second stage after
the interim analysis (this is possible if for the one-sided
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true), the results of the interim analysis can be taken
into account for a recalculation of the required sample
size. If the sample size recalculation leads to the conclu-
sion that more than 1200 patients are required, the
study is stopped, because the related treatment group
difference is judged to be of minor clinical importance.
Results of the interim analysis will be presented to the
Data Safety and Monitoring Board (DSMB) who will
advise the Steering Committee of the trial to either ter-
minate or to continue the trial.
Data Safety Monitoring Board (DSMB)
The DSMB of the trial will consist of three independent
members, who will not be involved in the trial. Two are
experts with broad experience in surgical RCTs and
have served already on DSMB boards and one is a
senior biostatistician. The DSMB will assess the Annual
Safety Report and will decide whether the trial will be
terminated or continued based on the results of the
interim analysis. In addition they will assess if one of
the termination criteria has been met or if there is any
other reason for an early termination of the trial and
promptly inform the Steering Committee about their
judgment.
Withdrawals
Patients are free to withdraw trial participation at their
own request at any time and without giving reasons for
their decision. Moreover, the primary investigator can
withdraw study patients, if continuation of the trial
would be detrimental to the patient’s well being. With-
drawals will be documented in the CRF and in the
patient’s medical records and all ongoing serious adverse
events have to be followed up.
Trial organization and administration
Funding
PROUD was started initially as a single center RCT
sponsored by the Department of Surgery, University of
Heidelberg, Germany. After a successful application this
trial is funded as a multicenter trial by a grant of €
500.000 of Johnson&Johnson Medical Limited, P.O. Box
1988, Kirkton Campus, Livingston EH54, Scotland.
Ethical considerations
Approval
The single center protocol of this trial was approved by
the ethics committee of the University of Heidelberg,
Germany on March 22, 2010 (Reference number: S-064/
2010). After funding was obtained by Johnson&Johnson
a substantial amendment was written and approved by
the ethics committee of the University of Heidelberg
(Date: 29.09.2010, reference number: S-064/2010) and
all other ethic committees of the participating centers
(between December 8, 2010 and January 11, 2011).
Registration
The trial protocol was registered with the German Clini-
cal Trials Register (DRKS; number 00000390) on April
27, 2010. The information was updated after the multi-
center protocol was approved by the ethics committee
of the University of Heidelberg on October 1, 2010.
Good Clinical Practice
The procedures set out in this trial protocol, pertaining
to the conduct, evaluation and documentation of this
trial, are designed to ensure that all persons involved in
the trial abide by Good Clinical Practice and the ethical
principles described in the current revision of the
Declaration of Helsinki. The trial will be carried out in
keeping with local legal and regulatory requirements.
Discussion
Surgical site infection (SSI) plays a pivotal role for pro-
longed treatment and further complications, increased
health care costs as well as reduced quality of life after
open abdominal surgery. They are believed to increase
the risk of dying 2-11 fold [19,20], with 77% of these
deaths attributed directly to the infection [21].
In the majority of surgical patients SSI was the conse-
quence of almost all interventions until the late 19
th
century. “Irritative fever” was followed by purulent drai-
nage from the incision and later as sepsis and oftentimes
death. When Joseph Lister, in the late 1860s, introduced
the principles of antisepsis postoperative infectious mor-
bidity substantially decreased [21]. Ever since there have
been substantial and successful efforts to further reduce
the number of affected patients and severity of infec-
tions with various means: hemostasis, conservation of
adequate blood supply, hypothermia prevention, atrau-
matic tissue handling, and infection control practices
such as improved operating room ventilation, sterilisa-
tion methods, and the use of antimicrobial prophylaxis
[22].
But SSI remain one of the most frequent complica-
tions after any type of surgery, ranging as high as 26%
depending on types of intervention and definitions of
wound infection. This can possibly be attributed in part
to the emergence of antibiotic-resistant micro-organ-
isms, larger numbers of elderly surgical patients or
those with a variety of chronic and immunocompromis-
ing conditions, and greater use of prosthetic implants
and organ transplantation [23].
Antimicrobial coated sutures have been amongst the
suggestions to further reduce SSI incidence and there is
a small number of studies evaluating triclosan coatings
in surgery [7,8,11,24]. Still the evaluation of new inter-
ventions in surgery remains a major challenge [25].
Given the evidence of two recent single center
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of more than 50% of wound infections by a triclosan
coated suture in abdominal surgery some surgeons
might question the demand for further trials. But treat-
ment effectiveness is best evaluated in randomized con-
trolled trials (RCT). The random allocation to one of
the treatment groups is the only method to ensure that
an observed effect can actually be attributed to the
effectiveness of the investigated procedure and not
known or unknown extraneous factors. Only RCTs gen-
erate data leading to the practice of evidence based
medicine on a high level [26]. The Balliol recommenda-
tions for evaluating surgery recently have underlined the
importance of RCTs and furthermore the manufacturing
company has agreed to the funding of such a trial in
recognition of the importance of validating the pre-
viously mentioned trials in an improved, randomized
controlled design [27].
The analysis of the use of triclosan coated sutures in
laparotomy previously done by Justinger et al, however
big the sample size, has limitations. First of all, in the
sequential design that was employed over a period of 2
years, per definition internal validity cannot be assumed
with certainty. It is not at all unlikely that over this rela-
tively long period of time other factors in the patients’
treatment might have changed and remained unrecorded
but may have contributed to the reduction in SSI.
Furthermore, with a control of PDS II
® sutures in history
the intervention group received Vicryl plus
® sutures, a
material different in structure (monofil versus braided)
and resorption (210 versus 70 days). Braided and non
braided sutures as well as rapidly absorbable and slowly
absorbable ones appear to differ in bacterial adherence
[28,29] and interrupted rapid absorbable sutures increase
the risk for development of an incisional hernia substan-
tially according to the INLINE systematic review [12].
At first PROUD was initiated as a single center RCT
and was transformed into a multicenter RCT once sub-
stantial funding was available. Due to this essential
amendment the assumptions were adapted to a more
conservative approach (reduction of SSI initially
assumed to be 73%, now 50%) and an adaptive design
given the uncertainties about the true rates of SSI and
the difference of SSI between the interventions. The
sample size was therefore increased from 200 to 750.
This amendment has not affected the interventions,
concomitant treatments (antibiotic prophylaxis) of
patients and documentation of endpoints. The definition
of the primary and secondary endpoints remained
unchanged and therefore patients from the single center
trial can be analyzed within the multicenter trial. It was
helpful to have the experience from the patients treated
initially to educate and train the participating centers
during the investigator meeting prior to the start of the
multicenter recruitment. Practical aspects such as mea-
surements of endpoints or taking and uploading of
photograps could be demonstrated to the other centers.
T h ee x p e r i e n c ef r o mt h eI N S E C Tt r i a la n dt h e
INLINE systematic review were important for the
PROUD trial in two ways. First of all, selection of suture
material (slowly absorbable) and suture technique (run-
ning suture) is based on the currently best available evi-
dence. INSECT has detected a high rate of wound
infections with 16% and PROUD will now show whether
a reduction is possible due to the use of antibacterial
coating. Secondly, study management was changed as
follows: Ethical approval was obtained for all participat-
ing center. Afterwards all centers received study related
material (sutures, cameras, case report forms) prior to
the start of patient recruitment. Finally, during a study
meeting all investigators were trained and received the
investigator site files. After this meeting each center was
able to start screening and randomizing patients imme-
diately. Whether this strategy will help to increase
patient recruitment and performance of centers has to
be shown in comparison to other RCTs that have been
performed by the SDGC.
The PROUD trial with a double blind, parallel group
design and independent assessment of wounds by
photographic documentation will be adequate to answer
the question whether SSI can be reduced by use of anti-
bacterial coated sutures.
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